T Cell News and Research

Latest T Cell News and Research

Study detects asymptomatic monkeypox virus infection

A new study published in the Annals of Internal Medicine aimed to assess the presence of MPVX in the anorectal samples of MSM who had undergone routine tests for sexually transmitted infections from 5th June to 11th July 2022.

17 Aug 2022

SARS-CoV-2 evolution within hosts and vaccination effects

A new study explores the mutational profiles within individuals infected with SARS-CoV-2.

16 Aug 2022

Superior protection with 'mix-and-match' COVID-19 booster strategy

Researchers discuss the durability and immunogenicity of homologous and heterologous booster regimens.

14 Aug 2022

In monkeys, spike-based vaccines produce some immunity based on CD8 T-cells

Scientists evaluate the role of CD8+ T-cells in vaccine protection against SARS-CoV-2 infection in rhesus macaques.

14 Aug 2022

How well does hybrid immunity protect against SARS-CoV-2 and its variants?

A new study explores the protection elicited by hybrid immunity against SARS-CoV-2 variants.

14 Aug 2022

Why is COVID-19 more severe in people older than 50?

A new study reports that the reduced efficiency of the immune response against SARS-CoV-2 could be due to the reduced diversity of both B- and T-cells.

14 Aug 2022

Experts urge FDA to include T cell responses when evaluating COVID vaccines

Now, a group of prominent scientists and physicians are urging the FDA to include in its guidance to vaccine developers a recommendation for T-cell assessment in COVID-19 vaccine clinical trials to more comprehensively measure immune response.

11 Aug 2022

Vaccines and monoclonal antibodies being developed for respiratory syncytial virus

A new study reviews recent advancements made in the development of RSV immunoprophylactic measures.

11 Aug 2022

OICR funding to help five research projects take the next step toward advancing cancer care

Five Ontario-based research projects will take the next step toward advancing cancer care in the province thanks to funding from the Ontario Institute for Cancer Research (OICR).

11 Aug 2022

Gut microbial and immune parameters linked to heterogeneous inter-personal COVID-19 vaccine-triggered immunity

A new study identified the gut microbial and immune variables linked to heterogeneous messenger ribonucleic acid (mRNA) COVID-19 vaccine responses between individuals.

11 Aug 2022

B-cell responses to COVID mRNA vaccine are enhanced by a 16-week interval between doses

Researchers assess the impact of extending the interval between primary and booster COVID-19 vaccine doses.

9 Aug 2022

Higher doses of CAR-T therapy achieve better survival rates for young patients with hard-to-treat B-ALL

Young people who received doses of tisagenlecleucel, a chimeric antigen receptor T cell (CAR-T) therapy, at the higher end of the FDA-approved dosing range had significantly better survival rates at one year compared with those who received lower doses within this range, according to research published today in Blood Advances.

8 Aug 2022

Gut microbiota-derived metabolites offer protection against SARS-CoV-2

A new study investigated how the gut microbiome confers immunity to mammalian hosts against SARS-CoV-2 intranasal infection by generating short-chain fatty acids.

5 Aug 2022

A combined influenza and COVID-19 mRNA vaccine

A combined mRNA vaccine is capable of inducing broad and durable protection against co-infection with SARS-CoV-2 and IAV,

3 Aug 2022

Hybrid immunity retained six months after SARS-CoV-2 exposure

Scientists hypothesize that lower death rates in COVID-19 patients may be due to hybrid immunity, as well as the reduced severity of Omicron infections.

3 Aug 2022

Memory B and T cell responses to the SARS-CoV-2 spike protein before and after the third BNT162b2 booster

Researchers evaluated memory B and T cell responses to SARS-CoV-2 before and after the third dose of the BNT162b2 vaccine.

3 Aug 2022

Shear-thinning biomaterial-based minimally invasive strategy for delivery of targeted immunotherapy

Researchers at the Terasaki Institute for Biomedical Innovation (TIBI) have developed and optimized a minimally invasive method for more targeted, efficient, and sustained delivery of immunotherapeutic treatments for cancer.

2 Aug 2022

Highly specialized T cells remain in blood 20 months after COVID-19

researchers analyze T-cell reactivity following recovery from COVID-19.

27 Jul 2022

The nose key to winning the war against COVID-19

researchers assess the respiratory mucosal immunity elicited by COVID-19 vaccination.

27 Jul 2022

Innovative technology reveals new insights into cellular reservoirs of HIV

In a presentation today at AIDS 2022, the 24th International AIDS Conference in Montreal, scientists with the National Institute of Allergy and Infectious Diseases' (NIAID) Vaccine Research Center (VRC) and their collaborators described how their use of cutting-edge technology revealed new insights into cellular reservoirs of HIV and what those observations could mean for the next steps in HIV cure research. NIAID is part of the National Institutes of Health.

27 Jul 2022